GlassScriptPhysician profile
Kevin Patel
NPI 1194013623
$25,550.05
in general payments reported to CMS, 2019-2025
14 companies · $5,738 in 2025
The $5,738 reported for 2025 was more than what 86% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $255 · 2021: $3,472 · 2022: $338 · 2023: $14K · 2024: $1,278 · 2025: $5,738.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $19K · Travel and Lodging: $1,565 · Food and Beverage: $924 · Education: $378.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $18,618.00 |
| Travel and Lodging | $1,564.81 |
| Food and Beverage | $924.09 |
| Education | $378.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $10,021.24 | 2021-2025 | Ocrevus, Ocrevus Zunovo |
| Tg Therapeutics, INC. | $7,210.96 | 2023-2025 | Briumvi |
| E.R. Squibb & Sons, L.L.C. | $5,341.47 | 2025 | |
| Genentech, INC. | $1,060.00 | 2021 | |
| Novartis Pharmaceuticals Corporation | $969.89 | 2020-2025 | |
| Biogen, INC. | $319.41 | 2021-2025 | Tysabri |
| Horizon Therapeutics Plc | $297.25 | 2021-2023 | Uplizna |
| Amgen INC. | $208.66 | 2024-2025 | Uplizna |
| Travere Therapeutics, INC. | $23.26 | 2020-2022 | |
| Bridgebio Pharma, INC. | $22.76 | 2025 | Attruby |
| Allergan, INC. | $22.56 | 2020 | |
| Glaxosmithkline, LLC. | $20.31 | 2024 | Trelegy Ellipta |
| Alexion Pharmaceuticals, INC. | $17.41 | 2025 | |
| Emd Serono, INC. | $14.87 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.